Vanda Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $24 from $22 and keeps a Buy rating on the shares after the FDA approved Bysanti, a first-line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults.